US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Warrior Met Coal LLC

46.79

-0.2600-0.55%

Post-market: 46.790.00000.00%18:27 EDT

Volume:798.23K

Turnover:37.19M

Market Cap:2.46B

PE:23.24

High:47.15

Open:46.03

Low:45.77

Close:47.05

Loading ...

Overview Company News Filings

Peabody Energy (BTU) Moves 9.2% Higher: Will This Strength Last?

Here’s Black Bear Value Fund’s Update on Warrior Met Coal (HCC)

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

Trump Set to Sign Executive Orders to Boost US Coal

BUZZ-Coal miners rise as Trump plans to sign executive orders to boost industry

RBC Capital Remains a Hold on Warrior Met Coal (HCC)

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

ACCESS Newswire

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update

Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Third Avenue Value Fund Exits Lazard Inc, Impacting Portfolio by -2.46%

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HCC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HCC\",,,,,undefined,":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":46.79,"timestamp":1749844800000,"preClose":47.05,"halted":0,"volume":798230,"hourTrading":{"tag":"盘后","latestPrice":46.79,"preClose":46.79,"latestTime":"18:27 EDT","volume":16635,"amount":778360.7702,"timestamp":1749853675919},"delay":0,"floatShares":51456964,"shares":52559285,"eps":2.013667,"marketStatus":"Market Closed","change":-0.26,"latestTime":"06-13 16:00:00 EDT","open":46.03,"high":47.1466,"low":45.765,"amount":37188681.593899995,"amplitude":0.029365,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.013667,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":47.05,"dividendRate":0.006839,"preHourTrading":{"tag":"盘前","latestPrice":47.28,"preClose":47.055,"latestTime":"09:07 EDT","volume":38,"amount":1778.70989,"timestamp":1749820059557},"postHourTrading":{"tag":"盘后","latestPrice":46.79,"preClose":46.79,"latestTime":"18:27 EDT","volume":16635,"amount":778360.7702,"timestamp":1749853675919},"volumeRatio":1.158188836231644,"impliedVol":0.5868,"impliedVolPercentile":0.86},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HCC\",,,,,undefined,":{"symbol":"HCC","floatShares":51456964,"roa":"2.18%","roe":"5.20%","lyrEps":4.792835,"volumeRatio":1.158188836231644,"shares":52559285,"dividePrice":0.32,"high":47.1466,"amplitude":0.029365,"preClose":47.05,"low":45.765,"week52Low":38,"pbRate":"1.18","psRate":"1.86","week52High":75.53,"institutionHeld":0.9048,"latestPrice":46.79,"eps":2.013667,"divideRate":0.006839,"volume":798230,"delay":0,"ttmEps":2.013667,"open":46.03,"prevYearClose":54.24,"prevWeekClose":47.44,"prevMonthClose":45.45,"prevQuarterClose":47.72,"fiveDayClose":47.44,"twentyDayClose":46.87,"sixtyDayClose":48.02},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HCC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526394915","title":"Peabody Energy (BTU) Moves 9.2% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526394915","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526394915?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:21","pubTimestamp":1744208460,"startTime":"0","endTime":"0","summary":"Peabody Energy  shares soared 9.2% in the last trading session to close at $11.26. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.1% loss over the past four weeks.Peabody Energy, is likely to gain from President Trump's recent executive order, aimed at revitalizing the coal industry. The new order is seen as a positive boost for the company, indicating a potential increase in coal demand and usage.Peabody Energy is expected to acquire Anglo American's steelmaking coal operations, strengthening its presence in the metallurgical coal market. The World Steel Association projects a rise in steel production volumes in 2025. This acquisition would benefit Peabody as demand for metallurgical coal is expected to grow.For Peabody Energy, the consensus EPS estimate for the quarter has been revised 25.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/peabody-energy-btu-moves-9-142100106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BTU","BK4156","HCC","BK4588","BK4585","BK4006"],"gpt_icon":0},{"id":"2526365577","title":"Here’s Black Bear Value Fund’s Update on Warrior Met Coal (HCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526365577","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526365577?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:04","pubTimestamp":1744200295,"startTime":"0","endTime":"0","summary":"Black Bear Value Partners, an investment management firm, published its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Black Bear Value Fund returned +0.8% in March and -1.3% YTD and the S&P 500 returned -5.7% in March and -4.3% YTD. HFRI Value Index returned -2.0% in March and -0.5% YTD. In addition, please check the fund’s top five holdings to know its best picks in 2025.In its first quarter 2025 investor letter, Black Bear Value Fund emphasized stocks such as Warrior Met Coal, Inc. . Warrior Met Coal, Inc.  produces and exports non-thermal metallurgical coal for the steel industry. The one-month return of Warrior Met Coal, Inc.  was -11.13%, and its shares lost 27.58% of their value over the last 52 weeks. On April 8, 2025, Warrior Met Coal, Inc.  stock closed at $43.44 per share with a market capitalization of $2.28 billion.Black Bear Value Fund stated the following regarding Warrior Met Coal, Inc.  in its Q1 2025 investor letter:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/black-bear-value-fund-warrior-120455758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCC","BK4006"],"gpt_icon":0},{"id":"2526840536","title":"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840536","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840536?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:36","pubTimestamp":1744140960,"startTime":"0","endTime":"0","summary":"Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1. The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date. In the CheckMate-8HW trial, Opdivo plus Yervoy demonstrated a 38% reduction in the risk of disease progression or death vs. Opdivo monotherapy in immunotherapy-nave patients across all lines of therapy .1 Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy  and was 39.3 months with Opdivo monotherapy .1 PFS rates at 12-, 24-, and 36-months were also numerically higher","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-approves-193600303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","LU1032466523.USD","LU1718418525.SGD","LU1093756168.USD","CRT","BMY","CRC","LU1323610961.USD","LU1989771016.USD","LU0061475181.USD","LU0225284248.USD","ORR","LU1670711123.USD","OS","LU1585245621.USD","LU1670711040.USD","BK4211","LU1670710661.SGD","BK4534","HSCT","VOD","LU0237698245.USD","LU2242646821.SGD","BK4532","LU0868494617.USD","LU2242652126.USD","LU1074936037.SGD","BK4006","IE00BFTCPJ56.SGD","LU1868837300.USD","IE00B2B36J28.USD","PFS","HCC","LU0985481810.HKD","LU1093756325.SGD","LU0114720955.EUR","IE00BSNM7G36.USD","BK4144","IE0009355771.USD","LU1670710588.SGD","LU1868836757.USD","BK4124","BK4195","LU2133065610.SGD","LU0225771236.USD","BK4581","LU1868837136.USD","LU1261432733.SGD","TEN","BK4132"],"gpt_icon":0},{"id":"2525956748","title":"Trump Set to Sign Executive Orders to Boost US Coal","url":"https://stock-news.laohu8.com/highlight/detail?id=2525956748","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525956748?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:12","pubTimestamp":1744121556,"startTime":"0","endTime":"0","summary":"WASHINGTON, April 8 (Reuters) - U.S. President Donald Trump will sign executive orders on Tuesday to boost the coal industry, a senior White House official and two sources told Reuters, in his latest ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL2N3QM0CK:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Trump Set to Sign Executive Orders to Boost US Coal","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNR","ARLP","TECK","HCC","METC","NRP","NC","SXC","BTU","HNRG","AMR"],"gpt_icon":1},{"id":"2525813327","title":"BUZZ-Coal miners rise as Trump plans to sign executive orders to boost industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2525813327","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525813327?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:52","pubTimestamp":1744120328,"startTime":"0","endTime":"0","summary":"BUZZ-Coal miners rise as Trump plans to sign executive orders to boost industry** Shares of coal miners rise as U.S. President Donald Trump plans to sign executive orders on Tuesday aimed at boosting ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL3N3QM19M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4086","BK4156","BHP.AU","BK7511","BK4585","BTU","HCC","CNR","BK4588","BK7095","BK7507"],"gpt_icon":0},{"id":"2524732424","title":"RBC Capital Remains a Hold on Warrior Met Coal (HCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524732424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524732424?lang=en_us&edition=fundamental","pubTime":"2025-04-03 09:47","pubTimestamp":1743644870,"startTime":"0","endTime":"0","summary":"In a report released on April 1, Sam Crittenden from RBC Capital maintained a Hold rating on Warrior Met Coal (HCC – Research Report), with a price...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-warrior-met-coal-hcc-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-warrior-met-coal-hcc-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4006","HCC"],"gpt_icon":0},{"id":"2524413515","title":"Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2524413515","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524413515?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:35","pubTimestamp":1743608114,"startTime":"0","endTime":"0","summary":"Sunshine Biopharma&#39;s K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44609792/nano-cap-sunshine-biopharma-stock-shoots-higher-on-encouraging-preclinical-data-from-potential-mrna-based-liver-cancer-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBFM","BK4139","BK1543","00509","BK1113","HCC","BK4006"],"gpt_icon":0},{"id":"2524493344","title":"Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2524493344","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524493344?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle  product as a novel therapeutic agent for human hepatocellular carcinoma.Human hepatocellular carcinoma  is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several treatment options were made available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.About Sunshine Biopharma Inc.Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-announces-positive-results-120000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","HCC","SBFMW","SBFM","BK4006"],"gpt_icon":0},{"id":"2523945783","title":"iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of  Zio® Long-Term Continuous Monitoring for Arrhythmia Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945783","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945783?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:05","pubTimestamp":1743422700,"startTime":"0","endTime":"0","summary":"Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052252/0/en/iRhythm-Unveils-New-Real-World-Data-at-ACC-25-Demonstrating-the-Benefits-of-Zio-Long-Term-Continuous-Monitoring-for-Arrhythmia-Detection.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4082","IRTC","BK4006","FL","BK4094","BK4588","BK4585","BK4563","HCC","BK4231","SRC"],"gpt_icon":0},{"id":"2523491061","title":"IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523491061","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523491061?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone. WILMINGTON, Del., March 31, 2025----AstraZeneca’s IMFINZI  in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy  has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer .The approval was granted by the Food and Drug Administration  after securing Priority Review and was based on results from the NIAGARA Phase III trial which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology  Congress and simultaneously published in The New England Journal of Medicine.In the trial, patients were treated with four cycles of IMFI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-approved-us-first-110000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","BK4006","TEN","LU1829250122.USD","LU2417539215.USD","BK4566","OS","BK4144","VOD","BK4097","BK4023","CRT","LU0889565916.HKD","IE00BFMHRM44.USD","BK4124","BK4585","LU2456880835.USD","HSCT","LU2236285917.USD","BK4568","LU0320765992.SGD","BK4532","NICE","BK4543","LU2462157665.USD","BK4007","LU0109394709.USD","BK4213","BK4132","BK4588","HCC"],"gpt_icon":0},{"id":"2522057297","title":"bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2522057297","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522057297?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:00","pubTimestamp":1743166800,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc.  and Can-Fite BioPharma Ltd.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 29, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Motti Farbstein, Chief Executive Officer of Can-Fite, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential regulatory and sales milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. With advanced-stage assets targeting unmet medical needs in markets with a combined value in excess of $70 billion, Can-Fite believes that it is well positioned for the poten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-fite-biopharma-interviews-130000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","ET","AIRI","HCC","BK4144","BK4100","BK4585","BK4604","TM","BK4555","BK4581","BK4588","BK4187","BK4006","CANF","TV","BK4561","BIAFW","BIAF","03160","BK4099"],"gpt_icon":0},{"id":"2522853184","title":"Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853184?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106200,"startTime":"0","endTime":"0","summary":"-- Granted Both Orphan Drug & Fast Track designations for Amezalpat  for the treatment of patients with Hepatocellular Carcinoma . -- Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial. -- Received FDA \"Study May Proceed\" letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis . \"2024 was another year filled with significant progress and milestone achievements that position Tempest for a successful future,\" said Stephen Brady, president and chief executive officer of Tempest. \"Despite challenging capital markets, our lean team excelled, reporting key OS data from the ongoing randomized Phase 2 trial of amezalpat in first-line hepatocellular carcinoma. As previously announced, we have secured broad regulatory agreement with both the FDA and EMA on the Phase 3 plan and received both Orphan Drug and Fast Track designations from the FDA. We also advanced our second clinical program, TPST","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4232","R","BK4139","BK4202","HCC","TPST","BK4006","NCI","BK4022","OS"],"gpt_icon":0},{"id":"2522539232","title":"Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539232?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -. - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer , BEACH301 for pediatric achondroplasia  and SURF301 for metastatic urothelial cancer  -. - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 -. \"2024 was a momentous year for TYRA and the patient communities we serve, highlighted by the positive interim results from our SURF301 study, which demonstrated a combination of high anti-tumor activity with favorable tolerability results in very sick, heavily pre-treated cancer patients. Importantly, the oncology doses tested in SURF301 are significantly higher than those to be tested in BEACH301, giving us confidence as we advance TYRA-300 in ACH,\" said Todd Harris, CEO of TYRA. \"Our conviction in TYRA-300 has never been stronger and we are working diligently to advance this potential b","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4503","BK4166","BK4006","QD","TYRA","BK4195","BK4563","BK4211","PR","CR","BK4161","BK4139","BK4153","HCC","BK4213","ACH","PFS"],"gpt_icon":0},{"id":"2522361927","title":"Junshi Biosciences Announces Toripalimab’s Approval in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2522361927","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522361927?lang=en_us&edition=fundamental","pubTime":"2025-03-27 09:00","pubTimestamp":1743037200,"startTime":"0","endTime":"0","summary":"SHANGHAI, March  26, 2025  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3050235/0/en/Junshi-Biosciences-Announces-Toripalimab-s-Approval-in-Singapore.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4161","RCC","HCC","CR"],"gpt_icon":0},{"id":"2522615804","title":"Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522615804","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522615804?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:15","pubTimestamp":1742994900,"startTime":"0","endTime":"0","summary":"– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –。– CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status –。– Exelixis is prepared to immediately support these new indications –。ALAMEDA, Calif., March 26, 2025----Exelixis, Inc.  today announced that the U.S. Food and Drug Administration  has approved CABOMETYX  for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors ; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET . NET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-announces-u-fda-approval-131500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4190","NCI","BK4613","DTC","LU2286300806.USD","IE00B66KJ199.SGD","BK4585","IE00B19Z4B17.USD","HCC","BK4560","IE0031619046.USD","BK4588","BK4554","IE00B7SZL793.SGD","EXEL","NET","BK4006","BK4157","BK4202","RCC","AEIS","BK4116","BK4548","BK4532","BK4607"],"gpt_icon":0},{"id":"2522835736","title":"Third Avenue Value Fund Exits Lazard Inc, Impacting Portfolio by -2.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522835736","media":"GuruFocus.com","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522835736?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:01","pubTimestamp":1742936465,"startTime":"0","endTime":"0","summary":"Exploring the Strategic Moves of Third Avenue Value Fund  in Q1 2025. GuruFocus has detected 2 Warning Sign with XTER:BMW.Third Avenue Value Fund  recently submitted its N-PORT filing for the first quarter of 2025, shedding light on its strategic investment decisions during this period. Founded by the legendary value investor Martin J. Whitman in 1990, the Third Avenue Value Fund  is renowned for its flexible investment strategy. The fund adopts a global, all-cap equities approach, allowing for opportunistic investments across the capital structure. It focuses on financial strength, the ability to compound NAV, and investments priced at a significant discount to the fund's conservative NAV estimate. The fund aims to build a differentiated portfolio by investing in contrarian and special-situation opportunities across various sectors, geographies, and security types, seeking long-term capital appreciation.Third Avenue Value Fund  added a total of one stock during the first quarter of 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/third-avenue-value-fund-exits-210105130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4127","CMA","LAZ","BK4588","BK4006","BK4207","BK4585","BK4211","HCC","BK4589"],"gpt_icon":0},{"id":"2522838780","title":"Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522838780","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522838780?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:40","pubTimestamp":1742935200,"startTime":"0","endTime":"0","summary":"First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors. New data from the treatment-refractory hepatocellular carcinoma  cohort of the BOT/BAL Phase 1 trial to be presented. LEXINGTON, Mass., March 25, 2025----Agenus Inc. , a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research  Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab , including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced hepatocellular carcinoma  cohort of a Phase 1 study evaluating BOT/BAL in patients with advanced solid tumors. Data from two separate, independent studies of neoadjuvant treatment with BOT/BAL in colorectal cancer--UNICORN and NEST-- were presented earlier this y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-present-bot-bal-data-204000586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BAL","BK4139","HCC","AGEN"],"gpt_icon":0},{"id":"2521726267","title":"Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2521726267","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521726267?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:00","pubTimestamp":1742821200,"startTime":"0","endTime":"0","summary":"The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March  24, 2025  (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047925/0/en/Can-Fite-Initiates-Pivotal-Phase-3-Psoriasis-Study-of-its-Oral-Drug-Piclidenoson-with-FDA-EMA-Approved-Protocol.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","HCC","BK4585","BK4006","MAA","BK4588"],"gpt_icon":0},{"id":"2521747504","title":"Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747504?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses. SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index. Cash balance of $85.2 million provides runway into late 2026. SAN DIEGO and SUZHOU, China, March 24, 2025  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel anti-body-based therapies, today reported financial results for the full year 2024 and provided corporate updates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adagene-reports-full-2024-financial-120000486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0266512127.USD","MSS","ADAG","CRC","BK4139","BK4213","LU0456854461.SGD","HCC","BK4113","BK4006"],"gpt_icon":0},{"id":"2520645247","title":"Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2520645247","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520645247?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:45","pubTimestamp":1742478300,"startTime":"0","endTime":"0","summary":"Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch  Ram","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046342/0/en/Can-Fite-Partner-Vetbiolix-Accelerate-Piclidenoson-Development-with-Advanced-Clinical-Trial-for-Canine-Osteoarthritis-in-a-3-8-Billion-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","AAQC","IE0031619046.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","HCC","BK4157","BK4006","AEIS"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":138,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HCC\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"HCC","amount":0.08,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-05","defaultRemindTime":1746451800000,"name":"Warrior Met Coal LLC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-05-05","currency":"USD","dateTimestamp":1746417600000,"payDate":"2025-05-12"},{"market":"US","date":"2025-04-30","symbol":"HCC","fiscalQuarterEnding":"2025/03","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745985600000,"reportTimeType":"post","actualEps":-0.16},{"date":"2025-02-24","symbol":"HCC","amount":0.08,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Warrior Met Coal LLC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"},{"date":"2025-02-13","symbol":"HCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.53,"defaultRemindTime":1739480400000,"name":null,"time":"Post Market","dateTimestamp":1739422800000,"actualEps":null},{"date":"2024-11-05","symbol":"HCC","amount":0.08,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-05","defaultRemindTime":1730817000000,"name":"Warrior Met Coal LLC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-12","payableDate":"2024-11-05","currency":"USD","dateTimestamp":1730782800000,"payDate":"2024-11-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HCC\",market:\"US\",,,undefined,":[{"executeDate":"2017-05-25","recordDate":"2017-05-30","paymentDate":"2017-06-13","value":0.05,"currency":"USD"},{"executeDate":"2017-08-10","recordDate":"2017-08-14","paymentDate":"2017-08-23","value":0.05,"currency":"USD"},{"executeDate":"2017-11-02","recordDate":"2017-11-03","paymentDate":"2017-11-10","value":0.05,"currency":"USD"},{"executeDate":"2017-11-24","recordDate":"2017-11-13","paymentDate":"2017-11-22","value":11.21,"currency":"USD"},{"executeDate":"2018-02-22","recordDate":"2018-02-23","paymentDate":"2018-03-02","value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.1667,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1667,"analysts":6,"updateTime":1712808000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HCC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HCC","date":"2025-06-13","current":23.45195,"percent":0.921697,"low":-75.380251,"twenty":-10.643728,"median":5.376398,"eighty":9.974476,"high":69.41615,"avg":2.443255,"sd":22.92253,"marketCap":2472914359},"quantilePoints":[{"date":"2020-06-19","current":3.626033,"twenty":1.655772,"median":2.53894,"eighty":3.173533,"marketCap":771608870},{"date":"2020-06-26","current":3.556301,"twenty":1.658309,"median":2.569547,"eighty":3.223807,"marketCap":756770238},{"date":"2020-07-02","current":3.58756,"twenty":1.668892,"median":2.578348,"eighty":3.233908,"marketCap":763422039},{"date":"2020-07-10","current":3.674123,"twenty":1.672645,"median":2.581956,"eighty":3.266791,"marketCap":781842410},{"date":"2020-07-17","current":3.823204,"twenty":1.67604,"median":2.584621,"eighty":3.281873,"marketCap":813566382},{"date":"2020-07-24","current":3.830418,"twenty":1.677444,"median":2.593675,"eighty":3.321451,"marketCap":815101413},{"date":"2020-07-31","current":3.828013,"twenty":1.678223,"median":2.601117,"eighty":3.349079,"marketCap":814589736},{"date":"2020-08-07","current":9.647015,"twenty":1.680377,"median":2.606673,"eighty":3.362554,"marketCap":753962429},{"date":"2020-08-14","current":10.295388,"twenty":1.681997,"median":2.613044,"eighty":3.385333,"marketCap":804636075},{"date":"2020-08-21","current":9.561875,"twenty":1.685395,"median":2.623886,"eighty":3.399229,"marketCap":747308314},{"date":"2020-08-28","current":10.177502,"twenty":1.686175,"median":2.628223,"eighty":3.407979,"marketCap":795422685},{"date":"2020-09-04","current":11.087845,"twenty":1.686798,"median":2.636324,"eighty":3.421132,"marketCap":866570531},{"date":"2020-09-11","current":11.716571,"twenty":1.68751,"median":2.638037,"eighty":3.438505,"marketCap":915708612},{"date":"2020-09-18","current":13.622397,"twenty":1.688347,"median":2.640623,"eighty":3.481761,"marketCap":1064658420},{"date":"2020-09-25","current":11.592136,"twenty":1.6895,"median":2.654273,"eighty":3.510467,"marketCap":905983367},{"date":"2020-10-02","current":11.461151,"twenty":1.692021,"median":2.657169,"eighty":3.536003,"marketCap":895746267},{"date":"2020-10-09","current":10.852073,"twenty":1.693794,"median":2.659661,"eighty":3.541374,"marketCap":848143751},{"date":"2020-10-16","current":9.981025,"twenty":1.69644,"median":2.662192,"eighty":3.558021,"marketCap":780067035},{"date":"2020-10-23","current":9.77145,"twenty":1.699397,"median":2.668416,"eighty":3.571019,"marketCap":763687674},{"date":"2020-10-30","current":41.058448,"twenty":1.701282,"median":2.677261,"eighty":3.586328,"marketCap":767792985},{"date":"2020-11-06","current":46.094951,"twenty":1.702293,"median":2.681102,"eighty":3.595833,"marketCap":861975591},{"date":"2020-11-13","current":47.518311,"twenty":1.702545,"median":2.691141,"eighty":3.610915,"marketCap":888592414},{"date":"2020-11-20","current":45.301155,"twenty":1.705418,"median":2.698396,"eighty":3.630957,"marketCap":847131593},{"date":"2020-11-27","current":50.501891,"twenty":1.708225,"median":2.702029,"eighty":3.645226,"marketCap":944385371},{"date":"2020-12-04","current":50.200796,"twenty":1.712405,"median":2.708224,"eighty":3.651736,"marketCap":938754889},{"date":"2020-12-11","current":53.266494,"twenty":1.718193,"median":2.715221,"eighty":3.674123,"marketCap":996083432},{"date":"2020-12-18","current":52.116857,"twenty":1.724567,"median":2.722503,"eighty":3.681994,"marketCap":974585228},{"date":"2020-12-24","current":54.41613,"twenty":1.731322,"median":2.730143,"eighty":3.690191,"marketCap":1017581636},{"date":"2020-12-31","current":58.357741,"twenty":1.733792,"median":2.736533,"eighty":3.700573,"marketCap":1091289762},{"date":"2021-01-08","current":62.573075,"twenty":1.734571,"median":2.739414,"eighty":3.729427,"marketCap":1170116509},{"date":"2021-01-15","current":63.011032,"twenty":1.734571,"median":2.74358,"eighty":3.73653,"marketCap":1178306300},{"date":"2021-01-22","current":63.750084,"twenty":1.737638,"median":2.753445,"eighty":3.748375,"marketCap":1192126574},{"date":"2021-01-29","current":63.011032,"twenty":1.738451,"median":2.763997,"eighty":3.76196,"marketCap":1178306300},{"date":"2021-02-05","current":59.917962,"twenty":1.739084,"median":2.770528,"eighty":3.795059,"marketCap":1120465896},{"date":"2021-02-12","current":59.972707,"twenty":1.751068,"median":2.780387,"eighty":3.813586,"marketCap":1121489620},{"date":"2021-02-19","current":62.217235,"twenty":1.754476,"median":2.788807,"eighty":3.819331,"marketCap":1163462303},{"date":"2021-02-26","current":-27.522655,"twenty":1.738929,"median":2.788676,"eighty":3.821762,"marketCap":984237661},{"date":"2021-03-05","current":-29.015798,"twenty":1.734259,"median":2.773691,"eighty":3.819331,"marketCap":1037633966},{"date":"2021-03-12","current":-27.623155,"twenty":1.713828,"median":2.767514,"eighty":3.815896,"marketCap":987831643},{"date":"2021-03-19","current":-26.824757,"twenty":1.702293,"median":2.759626,"eighty":3.813856,"marketCap":959280129},{"date":"2021-03-26","current":-24.598934,"twenty":1.693794,"median":2.745406,"eighty":3.813586,"marketCap":879682474},{"date":"2021-04-01","current":-24.21121,"twenty":1.688191,"median":2.743396,"eighty":3.812219,"marketCap":865817076},{"date":"2021-04-09","current":-24.21121,"twenty":1.683836,"median":2.738063,"eighty":3.806727,"marketCap":865817076},{"date":"2021-04-16","current":-26.724236,"twenty":1.677132,"median":2.73151,"eighty":3.800096,"marketCap":955685396},{"date":"2021-04-23","current":-25.101539,"twenty":1.656787,"median":2.726002,"eighty":3.796478,"marketCap":897656138},{"date":"2021-04-30","current":-22.760835,"twenty":1.647197,"median":2.715477,"eighty":3.791464,"marketCap":813950217},{"date":"2021-05-07","current":-10.548309,"twenty":1.639558,"median":2.709968,"eighty":3.783289,"marketCap":829740549},{"date":"2021-05-14","current":-10.633271,"twenty":1.625315,"median":2.703037,"eighty":3.772709,"marketCap":836423714},{"date":"2021-05-21","current":-11.417532,"twenty":1.623446,"median":2.698396,"eighty":3.763727,"marketCap":898114461},{"date":"2021-05-28","current":-11.959979,"twenty":1.618983,"median":2.691141,"eighty":3.76092,"marketCap":940783894},{"date":"2021-06-04","current":-12.639672,"twenty":1.616389,"median":2.684106,"eighty":3.7594,"marketCap":994249209},{"date":"2021-06-11","current":-11.646274,"twenty":1.610217,"median":2.677633,"eighty":3.754101,"marketCap":916107595},{"date":"2021-06-18","current":-10.679019,"twenty":1.607185,"median":2.669809,"eighty":3.752198,"marketCap":840022341},{"date":"2021-06-25","current":-11.59399,"twenty":1.60173,"median":2.662192,"eighty":3.7471,"marketCap":911994879},{"date":"2021-07-02","current":-11.299893,"twenty":1.598085,"median":2.660741,"eighty":3.746622,"marketCap":888860849},{"date":"2021-07-09","current":-11.541706,"twenty":1.592628,"median":2.658582,"eighty":3.744712,"marketCap":907882162},{"date":"2021-07-16","current":-11.20186,"twenty":1.586716,"median":2.65578,"eighty":3.73653,"marketCap":881149505},{"date":"2021-07-23","current":-11.567848,"twenty":1.582047,"median":2.642877,"eighty":3.73653,"marketCap":909938521},{"date":"2021-07-30","current":-12.201793,"twenty":1.573919,"median":2.638293,"eighty":3.733802,"marketCap":959805208},{"date":"2021-08-06","current":-13.112285,"twenty":1.568818,"median":2.637581,"eighty":3.733802,"marketCap":972682403},{"date":"2021-08-13","current":-12.446968,"twenty":1.562592,"median":2.631646,"eighty":3.729427,"marketCap":923328539},{"date":"2021-08-20","current":-13.015259,"twenty":1.533021,"median":2.623886,"eighty":3.72251,"marketCap":965484964},{"date":"2021-08-27","current":-15.461685,"twenty":1.519792,"median":2.616296,"eighty":3.703801,"marketCap":1146963235},{"date":"2021-09-03","current":-17.090325,"twenty":1.517791,"median":2.607623,"eighty":3.702437,"marketCap":1267777381},{"date":"2021-09-10","current":-18.330863,"twenty":1.506877,"median":2.604719,"eighty":3.700946,"marketCap":1359801773},{"date":"2021-09-17","current":-16.182445,"twenty":1.50136,"median":2.597695,"eighty":3.699883,"marketCap":1200429921},{"date":"2021-09-24","current":-14.990419,"twenty":1.491466,"median":2.590275,"eighty":3.69463,"marketCap":1112004248},{"date":"2021-10-01","current":-17.665547,"twenty":1.437809,"median":2.583354,"eighty":3.691387,"marketCap":1310447909},{"date":"2021-10-08","current":-18.62887,"twenty":1.417229,"median":2.579596,"eighty":3.688084,"marketCap":1381908192},{"date":"2021-10-15","current":-18.317003,"twenty":-4.135408,"median":2.572321,"eighty":3.686335,"marketCap":1358773568},{"date":"2021-10-22","current":-17.603173,"twenty":-4.510213,"median":2.5394,"eighty":3.684309,"marketCap":1305820985},{"date":"2021-10-29","current":-16.612128,"twenty":-4.706327,"median":2.532428,"eighty":3.680121,"marketCap":1232304291},{"date":"2021-11-05","current":-54.762812,"twenty":-4.859084,"median":2.521967,"eighty":3.677059,"marketCap":1167543151},{"date":"2021-11-12","current":-54.979838,"twenty":-4.941339,"median":2.515293,"eighty":3.676527,"marketCap":1172170138},{"date":"2021-11-19","current":-50.808122,"twenty":-5.127728,"median":2.433754,"eighty":3.674604,"marketCap":1083229158},{"date":"2021-11-26","current":-51.362743,"twenty":-5.252528,"median":2.414858,"eighty":3.674123,"marketCap":1095053682},{"date":"2021-12-03","current":-53.123062,"twenty":-5.611529,"median":2.40502,"eighty":3.665747,"marketCap":1132583691},{"date":"2021-12-10","current":-54.232305,"twenty":-5.755373,"median":2.350665,"eighty":3.656822,"marketCap":1156232737},{"date":"2021-12-17","current":-57.415348,"twenty":-10.37185,"median":2.326995,"eighty":3.653327,"marketCap":1224095219},{"date":"2021-12-23","current":-61.56295,"twenty":-10.599286,"median":2.309178,"eighty":3.651736,"marketCap":1312522089},{"date":"2021-12-31","current":-61.997001,"twenty":-10.714311,"median":2.30567,"eighty":3.650401,"marketCap":1321776064},{"date":"2022-01-07","current":-62.551622,"twenty":-10.856785,"median":2.304,"eighty":3.648657,"marketCap":1333600587},{"date":"2022-01-14","current":-66.55454,"twenty":-11.03063,"median":2.299612,"eighty":3.646023,"marketCap":1418942799},{"date":"2022-01-21","current":-62.334597,"twenty":-11.190096,"median":2.295173,"eighty":3.645248,"marketCap":1328973600},{"date":"2022-01-28","current":-63.443839,"twenty":-11.25153,"median":2.293323,"eighty":3.644889,"marketCap":1352622647},{"date":"2022-02-04","current":-69.327646,"twenty":-11.379626,"median":2.286804,"eighty":3.642707,"marketCap":1478065416},{"date":"2022-02-11","current":-73.981641,"twenty":-11.424067,"median":2.276675,"eighty":3.635881,"marketCap":1577288590},{"date":"2022-02-18","current":-75.380251,"twenty":-11.527328,"median":2.273681,"eighty":3.62589,"marketCap":1607106953},{"date":"2022-02-25","current":10.752414,"twenty":-11.5221,"median":2.276675,"eighty":3.645162,"marketCap":1622334987},{"date":"2022-03-04","current":13.090637,"twenty":-11.476351,"median":2.285809,"eighty":3.650617,"marketCap":1975128468},{"date":"2022-03-11","current":14.234148,"twenty":-11.443674,"median":2.292953,"eighty":3.674123,"marketCap":2147662506},{"date":"2022-03-18","current":13.142137,"twenty":-11.424067,"median":2.295173,"eighty":3.679184,"marketCap":1982898730},{"date":"2022-03-25","current":13.066882,"twenty":-11.424067,"median":2.299612,"eighty":3.690894,"marketCap":1971544287},{"date":"2022-04-01","current":12.971104,"twenty":-11.417532,"median":2.304,"eighty":3.702437,"marketCap":1957093177},{"date":"2022-04-08","current":12.868485,"twenty":-11.39139,"median":2.30567,"eighty":3.733802,"marketCap":1941609845},{"date":"2022-04-14","current":13.569718,"twenty":-11.386161,"median":2.308491,"eighty":3.738166,"marketCap":2047412614},{"date":"2022-04-22","current":11.298406,"twenty":-11.36394,"median":2.326995,"eighty":3.75363,"marketCap":1704714864},{"date":"2022-04-29","current":11.654154,"twenty":-11.348255,"median":2.350665,"eighty":3.7679,"marketCap":1758390415},{"date":"2022-05-06","current":5.191508,"twenty":-11.309043,"median":2.40502,"eighty":3.798629,"marketCap":1653417395},{"date":"2022-05-13","current":5.197995,"twenty":-11.263294,"median":2.414858,"eighty":3.813721,"marketCap":1655483521},{"date":"2022-05-20","current":5.376398,"twenty":-11.243687,"median":2.472508,"eighty":3.823204,"marketCap":1712301988},{"date":"2022-05-27","current":5.592102,"twenty":-11.241073,"median":2.517292,"eighty":3.828494,"marketCap":1781000680},{"date":"2022-06-03","current":5.866193,"twenty":-11.217545,"median":2.521967,"eighty":3.839442,"marketCap":1868294507},{"date":"2022-06-10","current":5.890521,"twenty":-11.197938,"median":2.532428,"eighty":3.86219,"marketCap":1876042480},{"date":"2022-06-17","current":5.476952,"twenty":-11.179639,"median":2.5394,"eighty":3.887139,"marketCap":1744326943},{"date":"2022-06-24","current":5.214214,"twenty":-11.122126,"median":2.569547,"eighty":3.909261,"marketCap":1660648836},{"date":"2022-07-01","current":4.816863,"twenty":-11.046315,"median":2.578972,"eighty":4.004025,"marketCap":1534098614},{"date":"2022-07-08","current":4.666032,"twenty":-11.034551,"median":2.581956,"eighty":4.305553,"marketCap":1486061183},{"date":"2022-07-15","current":4.907686,"twenty":-11.001874,"median":2.584621,"eighty":4.638461,"marketCap":1563024379},{"date":"2022-07-22","current":4.828216,"twenty":-10.933904,"median":2.593675,"eighty":4.813944,"marketCap":1537714335},{"date":"2022-07-29","current":5.178533,"twenty":-10.929983,"median":2.601117,"eighty":4.897306,"marketCap":1649285143},{"date":"2022-08-05","current":2.424599,"twenty":-10.885542,"median":2.602918,"eighty":4.942718,"marketCap":1503634374},{"date":"2022-08-12","current":2.78275,"twenty":-10.769209,"median":2.601117,"eighty":4.897306,"marketCap":1725744570},{"date":"2022-08-19","current":2.883532,"twenty":-10.762674,"median":2.606673,"eighty":4.850273,"marketCap":1788245347},{"date":"2022-08-26","current":2.90602,"twenty":-10.753524,"median":2.613044,"eighty":4.828216,"marketCap":1802191801},{"date":"2022-09-02","current":2.655315,"twenty":-10.726075,"median":2.623886,"eighty":4.825945,"marketCap":1646714663},{"date":"2022-09-09","current":2.606173,"twenty":-10.679019,"median":2.621717,"eighty":4.816863,"marketCap":1616239078},{"date":"2022-09-16","current":2.333812,"twenty":-10.659413,"median":2.607733,"eighty":4.802266,"marketCap":1447332022},{"date":"2022-09-23","current":2.248855,"twenty":-10.646342,"median":2.605949,"eighty":4.683872,"marketCap":1394645418},{"date":"2022-09-30","current":2.368795,"twenty":-10.633271,"median":2.601176,"eighty":4.666032,"marketCap":1469027473},{"date":"2022-10-07","current":2.692797,"twenty":-10.548309,"median":2.602947,"eighty":4.640083,"marketCap":1669959853},{"date":"2022-10-14","current":2.765261,"twenty":-10.509096,"median":2.606173,"eighty":4.631973,"marketCap":1714898457},{"date":"2022-10-21","current":3.075936,"twenty":-10.450277,"median":2.610389,"eighty":4.409781,"marketCap":1907566266},{"date":"2022-10-28","current":3.08843,"twenty":-10.319566,"median":2.623886,"eighty":4.385454,"marketCap":1915314301},{"date":"2022-11-04","current":2.888992,"twenty":-6.057648,"median":2.626492,"eighty":4.335369,"marketCap":1964901726},{"date":"2022-11-11","current":2.590524,"twenty":-5.933659,"median":2.635068,"eighty":4.24592,"marketCap":1761903204},{"date":"2022-11-18","current":2.532805,"twenty":-5.933659,"median":2.635068,"eighty":4.24592,"marketCap":1722646492},{"date":"2022-11-25","current":2.695329,"twenty":-5.2582,"median":2.638393,"eighty":4.24592,"marketCap":1833185128},{"date":"2022-12-02","current":2.967976,"twenty":-5.2582,"median":2.645964,"eighty":4.24592,"marketCap":2018621437},{"date":"2022-12-09","current":2.695329,"twenty":-5.2582,"median":2.656981,"eighty":4.24592,"marketCap":1833185128},{"date":"2022-12-16","current":2.63761,"twenty":-5.2582,"median":2.657169,"eighty":4.24592,"marketCap":1793928416},{"date":"2022-12-23","current":2.75153,"twenty":-5.18405,"median":2.661998,"eighty":4.24592,"marketCap":1871408768},{"date":"2022-12-30","current":2.630775,"twenty":1.404132,"median":2.662192,"eighty":4.24592,"marketCap":1789279595},{"date":"2023-01-06","current":2.629256,"twenty":1.404132,"median":2.658582,"eighty":4.24592,"marketCap":1788246524},{"date":"2023-01-13","current":2.614826,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1778432346},{"date":"2023-01-20","current":2.909498,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1978848190},{"date":"2023-01-27","current":2.806211,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1908599337},{"date":"2023-02-03","current":2.875322,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1955604084},{"date":"2023-02-10","current":2.913295,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1981430868},{"date":"2023-02-17","current":3.373053,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":2163132093},{"date":"2023-02-24","current":2.987654,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1915976338},{"date":"2023-03-03","current":3.436207,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":2203632406},{"date":"2023-03-10","current":3.066191,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1966342111},{"date":"2023-03-17","current":2.689033,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1724471348},{"date":"2023-03-24","current":2.800096,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":1795696122},{"date":"2023-03-31","current":2.976014,"twenty":1.406003,"median":2.65495,"eighty":4.216104,"marketCap":1908512005},{"date":"2023-04-06","current":2.906296,"twenty":1.406003,"median":2.65495,"eighty":4.216104,"marketCap":1863801563},{"date":"2023-04-14","current":3.133287,"twenty":1.404132,"median":2.654586,"eighty":4.24592,"marketCap":2009370443},{"date":"2023-04-21","current":3.063568,"twenty":1.404132,"median":2.656974,"eighty":4.24592,"marketCap":1964660001},{"date":"2023-04-28","current":2.771722,"twenty":1.404132,"median":2.657169,"eighty":4.24592,"marketCap":1777500012},{"date":"2023-05-05","current":2.740192,"twenty":1.404132,"median":2.658582,"eighty":4.24592,"marketCap":1856003230},{"date":"2023-05-19","current":2.709489,"twenty":-3.288715,"median":2.658582,"eighty":4.355403,"marketCap":1835207675},{"date":"2023-05-26","current":2.572864,"twenty":-3.288715,"median":2.658582,"eighty":4.355403,"marketCap":1742667458},{"date":"2023-06-02","current":2.563653,"twenty":-3.288715,"median":2.656144,"eighty":4.355403,"marketCap":1736428792},{"date":"2023-06-09","current":2.740192,"twenty":-3.288715,"median":2.656144,"eighty":4.355403,"marketCap":1856003230},{"date":"2023-06-16","current":2.770894,"twenty":-3.288715,"median":2.656977,"eighty":4.355403,"marketCap":1876798784},{"date":"2023-06-23","current":2.906753,"twenty":-5.632332,"median":2.661998,"eighty":4.36542,"marketCap":1968819112},{"date":"2023-06-30","current":2.978903,"twenty":-7.975949,"median":2.667532,"eighty":4.375437,"marketCap":2017688665},{"date":"2023-07-07","current":2.974298,"twenty":-7.975949,"median":2.669576,"eighty":4.375437,"marketCap":2014569332},{"date":"2023-07-14","current":3.000395,"twenty":-7.975949,"median":2.674943,"eighty":4.375437,"marketCap":2032245553},{"date":"2023-07-21","current":3.103248,"twenty":-7.975949,"median":2.685979,"eighty":4.375437,"marketCap":2101910660},{"date":"2023-07-28","current":3.259063,"twenty":-7.975949,"median":2.685979,"eighty":4.375437,"marketCap":2207448099},{"date":"2023-08-04","current":4.300459,"twenty":-7.975949,"median":2.689283,"eighty":4.404916,"marketCap":1988652498},{"date":"2023-08-11","current":4.570433,"twenty":-7.975949,"median":2.689283,"eighty":4.59563,"marketCap":2113495971},{"date":"2023-08-18","current":4.468067,"twenty":-7.975949,"median":2.697608,"eighty":4.598779,"marketCap":2066159488},{"date":"2023-08-25","current":4.417447,"twenty":-7.975949,"median":2.70915,"eighty":4.598779,"marketCap":2042751336},{"date":"2023-09-01","current":4.450069,"twenty":-7.975949,"median":2.713487,"eighty":4.598779,"marketCap":2057836589},{"date":"2023-09-08","current":4.685171,"twenty":-7.975949,"median":2.718459,"eighty":4.660842,"marketCap":2166554448},{"date":"2023-09-15","current":5.306111,"twenty":-7.975949,"median":2.726847,"eighty":4.770664,"marketCap":2453694437},{"date":"2023-09-22","current":5.214995,"twenty":-7.975949,"median":2.726847,"eighty":4.828216,"marketCap":2411559765},{"date":"2023-09-29","current":5.743694,"twenty":-7.975949,"median":2.726847,"eighty":4.944336,"marketCap":2656044900},{"date":"2023-10-06","current":5.586209,"twenty":-7.975949,"median":2.726847,"eighty":5.01406,"marketCap":2583219541},{"date":"2023-10-13","current":5.506342,"twenty":-7.975949,"median":2.726847,"eighty":5.085439,"marketCap":2546286680},{"date":"2023-10-20","current":5.371355,"twenty":-7.975949,"median":2.726847,"eighty":5.164092,"marketCap":2483864943},{"date":"2023-10-27","current":5.320735,"twenty":-10.37185,"median":2.7187,"eighty":5.183723,"marketCap":2460456792},{"date":"2023-11-03","current":5.632314,"twenty":-10.37185,"median":2.7187,"eighty":5.218575,"marketCap":2531201427},{"date":"2023-11-10","current":5.363861,"twenty":-10.37185,"median":2.7187,"eighty":5.29291,"marketCap":2410556891},{"date":"2023-11-17","current":5.898627,"twenty":-10.37185,"median":2.7187,"eighty":5.335852,"marketCap":2650884316},{"date":"2023-11-24","current":6.40214,"twenty":-10.37185,"median":2.7187,"eighty":5.365059,"marketCap":2877166631},{"date":"2023-12-01","current":6.478535,"twenty":-10.37185,"median":2.72267,"eighty":5.38029,"marketCap":2911499120},{"date":"2023-12-08","current":6.762123,"twenty":-10.345708,"median":2.726847,"eighty":5.40405,"marketCap":3038945481},{"date":"2023-12-15","current":6.477378,"twenty":-10.345708,"median":2.726847,"eighty":5.427885,"marketCap":2910978931},{"date":"2023-12-22","current":7.108216,"twenty":-10.37185,"median":2.72267,"eighty":5.478809,"marketCap":3194482061},{"date":"2023-12-29","current":7.112846,"twenty":-10.397993,"median":2.720685,"eighty":5.489704,"marketCap":3196562818},{"date":"2024-01-05","current":7.608257,"twenty":-10.424135,"median":2.7187,"eighty":5.542798,"marketCap":3419203808},{"date":"2024-01-12","current":7.309621,"twenty":-10.424135,"median":2.7187,"eighty":5.590923,"marketCap":3284994987},{"date":"2024-01-19","current":7.808504,"twenty":-10.450277,"median":2.718459,"eighty":5.669951,"marketCap":3509196545},{"date":"2024-01-26","current":7.412639,"twenty":-10.424135,"median":2.7187,"eighty":5.709874,"marketCap":3331291828},{"date":"2024-02-02","current":7.465884,"twenty":-10.424135,"median":2.7187,"eighty":5.766422,"marketCap":3355220533},{"date":"2024-02-09","current":6.990151,"twenty":-10.424135,"median":2.7187,"eighty":5.885655,"marketCap":3141422759},{"date":"2024-02-16","current":6.418502,"twenty":-10.424135,"median":2.7187,"eighty":6.101684,"marketCap":3072081326},{"date":"2024-02-23","current":6.286398,"twenty":-10.424135,"median":2.731024,"eighty":6.221043,"marketCap":3008852573},{"date":"2024-03-01","current":6.219801,"twenty":-10.397993,"median":2.739743,"eighty":6.294914,"marketCap":2976976920},{"date":"2024-03-08","current":6.701206,"twenty":-10.397993,"median":2.752304,"eighty":6.394269,"marketCap":3207391753},{"date":"2024-03-15","current":5.794309,"twenty":-10.397993,"median":2.757333,"eighty":6.40214,"marketCap":2773324387},{"date":"2024-03-22","current":6.171272,"twenty":-10.397993,"median":2.771308,"eighty":6.40214,"marketCap":2953749979},{"date":"2024-03-28","current":6.782062,"twenty":-10.397993,"median":2.782329,"eighty":6.419638,"marketCap":3246091735},{"date":"2024-04-05","current":6.157068,"twenty":-10.424135,"median":2.792386,"eighty":6.450017,"marketCap":2946951333},{"date":"2024-04-12","current":6.902254,"twenty":-10.424135,"median":2.806211,"eighty":6.478304,"marketCap":3303618735},{"date":"2024-04-19","current":7.227863,"twenty":-10.424135,"median":2.821174,"eighty":6.550936,"marketCap":3459464608},{"date":"2024-04-26","current":7.599363,"twenty":-10.397993,"median":2.831103,"eighty":6.604876,"marketCap":3637275337},{"date":"2024-05-03","current":7.904106,"twenty":-10.397993,"median":2.843363,"eighty":6.650657,"marketCap":3425173301},{"date":"2024-05-10","current":7.957211,"twenty":-10.397993,"median":2.851831,"eighty":6.739488,"marketCap":3448185612},{"date":"2024-05-17","current":7.69893,"twenty":-10.397993,"median":2.862085,"eighty":6.836555,"marketCap":3336262099},{"date":"2024-05-24","current":7.872726,"twenty":-10.397993,"median":2.873803,"eighty":6.918183,"marketCap":3411575117},{"date":"2024-05-31","current":8.030833,"twenty":-10.397993,"median":2.87874,"eighty":7.041081,"marketCap":3480089043},{"date":"2024-06-07","current":8.312045,"twenty":-10.397993,"median":2.890347,"eighty":7.110994,"marketCap":3601949691},{"date":"2024-06-14","current":7.809967,"twenty":-10.424135,"median":2.899357,"eighty":7.20537,"marketCap":3384378749},{"date":"2024-06-21","current":8.021177,"twenty":-10.450277,"median":2.908126,"eighty":7.318881,"marketCap":3475904987},{"date":"2024-06-28","current":7.420132,"twenty":-10.485568,"median":2.914426,"eighty":7.344392,"marketCap":3215447466},{"date":"2024-07-05","current":8.845502,"twenty":-10.485568,"median":2.921699,"eighty":7.399675,"marketCap":3833118816},{"date":"2024-07-12","current":8.297562,"twenty":-10.485568,"median":2.930616,"eighty":7.467301,"marketCap":3595673606},{"date":"2024-07-15","current":8.5486,"twenty":-10.485568,"median":2.931522,"eighty":7.489052,"marketCap":3704459076},{"date":"2024-08-02","current":8.040485,"twenty":-10.635885,"median":2.949925,"eighty":7.544826,"marketCap":3392746863},{"date":"2024-08-09","current":7.544899,"twenty":-10.635885,"median":2.968066,"eighty":7.555471,"marketCap":3183630662},{"date":"2024-08-16","current":7.220094,"twenty":-10.635885,"median":2.978269,"eighty":7.601142,"marketCap":3046576565},{"date":"2024-08-23","current":7.176704,"twenty":-10.635885,"median":3.000593,"eighty":7.601142,"marketCap":3028267812},{"date":"2024-08-30","current":7.621762,"twenty":-10.635885,"median":3.027721,"eighty":7.610958,"marketCap":3216063311},{"date":"2024-09-06","current":6.658504,"twenty":-10.635885,"median":3.039541,"eighty":7.610958,"marketCap":2809608986},{"date":"2024-09-13","current":6.653545,"twenty":-10.635885,"median":3.054202,"eighty":7.610958,"marketCap":2807516557},{"date":"2024-09-20","current":6.839502,"twenty":-10.635885,"median":3.066906,"eighty":7.610958,"marketCap":2885982643},{"date":"2024-09-27","current":7.775486,"twenty":-10.635885,"median":3.0801,"eighty":7.62201,"marketCap":3280928609},{"date":"2024-10-04","current":7.686227,"twenty":-10.635885,"median":3.097075,"eighty":7.668336,"marketCap":3243264888},{"date":"2024-10-11","current":7.834992,"twenty":-10.635885,"median":3.133196,"eighty":7.694477,"marketCap":3306037756},{"date":"2024-10-18","current":7.872184,"twenty":-10.635885,"median":3.155214,"eighty":7.749005,"marketCap":3321730974},{"date":"2024-10-25","current":7.435805,"twenty":-10.635885,"median":3.209618,"eighty":7.753419,"marketCap":3137597225},{"date":"2024-10-31","current":8.541869,"twenty":-10.635885,"median":3.232728,"eighty":7.761601,"marketCap":3231756528},{"date":"2024-11-08","current":10.339444,"twenty":-10.638499,"median":3.259831,"eighty":7.813587,"marketCap":3911856437},{"date":"2024-11-15","current":9.190464,"twenty":-10.638499,"median":3.349512,"eighty":7.829517,"marketCap":3477147598},{"date":"2024-11-22","current":10.06568,"twenty":-10.638499,"median":3.38558,"eighty":7.872401,"marketCap":3808279602},{"date":"2024-11-29","current":9.722783,"twenty":-10.638499,"median":3.436207,"eighty":7.907003,"marketCap":3678547000},{"date":"2024-12-06","current":9.213969,"twenty":-10.638499,"median":3.493783,"eighty":7.959307,"marketCap":3486040559},{"date":"2024-12-13","current":8.801939,"twenty":-10.638499,"median":3.56111,"eighty":7.998729,"marketCap":3330152190},{"date":"2024-12-20","current":7.723474,"twenty":-10.638499,"median":3.606796,"eighty":8.015391,"marketCap":2922122233},{"date":"2024-12-27","current":7.482893,"twenty":-10.638499,"median":3.652482,"eighty":8.015391,"marketCap":2831100165},{"date":"2025-01-03","current":7.527138,"twenty":-10.638499,"median":3.69336,"eighty":8.015391,"marketCap":2847839856},{"date":"2025-01-10","current":7.249225,"twenty":-10.641114,"median":3.763091,"eighty":8.01571,"marketCap":2742693675},{"date":"2025-01-17","current":7.516077,"twenty":-10.641114,"median":3.807574,"eighty":8.01571,"marketCap":2843654933},{"date":"2025-01-24","current":7.777397,"twenty":-10.641114,"median":3.823204,"eighty":8.01571,"marketCap":2942523731},{"date":"2025-01-31","current":7.391638,"twenty":-10.641114,"median":3.849654,"eighty":8.01571,"marketCap":2796574554},{"date":"2025-02-07","current":7.359837,"twenty":-10.641114,"median":3.926599,"eighty":8.01571,"marketCap":2784542901},{"date":"2025-02-14","current":11.29089,"twenty":-10.641114,"median":4.243374,"eighty":8.019246,"marketCap":2829530819},{"date":"2025-02-21","current":10.086516,"twenty":-10.641114,"median":4.394139,"eighty":8.037134,"marketCap":2527711235},{"date":"2025-02-28","current":10.426158,"twenty":-10.641114,"median":4.429258,"eighty":8.145007,"marketCap":2612826433},{"date":"2025-03-07","current":10.113771,"twenty":-10.643728,"median":4.464693,"eighty":8.287174,"marketCap":2534541467},{"date":"2025-03-14","current":10.126351,"twenty":-10.643728,"median":4.54681,"eighty":8.536641,"marketCap":2537693881},{"date":"2025-03-21","current":9.878343,"twenty":-10.643728,"median":4.631973,"eighty":8.801939,"marketCap":2475542323},{"date":"2025-03-28","current":10.547385,"twenty":-10.643728,"median":4.683872,"eighty":8.853227,"marketCap":2643206442},{"date":"2025-04-04","current":9.2093,"twenty":-10.643728,"median":4.802266,"eighty":9.064643,"marketCap":2307878204},{"date":"2025-04-11","current":9.17784,"twenty":-10.641114,"median":4.863283,"eighty":9.185414,"marketCap":2299994311},{"date":"2025-04-17","current":9.916094,"twenty":-10.641114,"median":4.957963,"eighty":9.291397,"marketCap":2485002994},{"date":"2025-04-25","current":10.524315,"twenty":-10.643728,"median":5.039055,"eighty":9.480855,"marketCap":2637424921},{"date":"2025-05-02","current":22.634497,"twenty":-10.643728,"median":5.095819,"eighty":9.629986,"marketCap":2386717131},{"date":"2025-05-09","current":22.574683,"twenty":-10.643728,"median":5.168875,"eighty":9.671535,"marketCap":2380410017},{"date":"2025-05-16","current":23.36223,"twenty":-10.643728,"median":5.214214,"eighty":9.722783,"marketCap":2463453687},{"date":"2025-05-23","current":22.335428,"twenty":-10.643728,"median":5.278206,"eighty":9.790675,"marketCap":2355181560},{"date":"2025-05-30","current":23.083099,"twenty":-10.643728,"median":5.313986,"eighty":9.852337,"marketCap":2434020488},{"date":"2025-06-06","current":23.222665,"twenty":-10.643728,"median":5.351129,"eighty":9.893342,"marketCap":2448737088},{"date":"2025-06-13","current":23.45195,"twenty":-10.643728,"median":5.376398,"eighty":9.974476,"marketCap":2472914359}],"updateTime":1749957141227}}}